Search Bar & Filters
Found 54 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating TQB6411 injection, an antibody-conjugated drug that targets EGFR and c-Met proteins on tumor cells, in people with advanced malignant tumors. The study aims to assess how well patients tolerate the treatment, understand how the drug moves through the body, and observe early signs of its effects. This phase I clinical trial focuses on patients who have advanced cancer and have not responded to or cannot tolerate standard treatments. TQB6411 is given by intravenous injection every three weeks, with doses ranging from 0.8 mgkg to 8 mgkg at the start of each treatment cycle. The antibody in TQB6411 binds to cancer cells to block important growth signals, and then releases toxins inside the cells to cause DNA damage and cell death. The study includes a dose escalation stage to find the maximum tolerated dose and a dose expansion stage for specific tumor types such as advanced non-small cell lung cancer and metastatic colon cancer. Participants will have regular blood tests and tumor imaging to monitor safety and treatment effects for up to 24 months. Researchers will track dose-limiting toxicities, adverse events, drug levels in the blood, tumor response rates, and survival outcomes. Women of childbearing potential must use effective contraception during and for six months after the study. The trial includes careful monitoring to assess the bodys reaction to the drug and to gather information for future studies.
Actively Recruiting
Researchers are evaluating the efficacy and safety of LBL-024 combination therapy for patients with advanced non-small cell lung cancer NSCLC, a type of advanced solid tumor. This open-label, multicenter Phase II study aims to understand how well LBL-024 works when given alongside other cancer drugs. The study includes four groups of participants to assess different drug combinations and treatment approaches. Participants receive LBL-024 combined with drugs such as docetaxel, bevacizumab, pemetrexed, carboplatin, or paclitaxel through intravenous infusion. Each group starts with a 21-day safety observation period to monitor tolerability, followed by randomized assignment to specific treatment arms if safety is confirmed. Some groups continue with maintenance therapy using LBL-024 or other drugs after initial combination treatment. During the trial, participants undergo regular assessments including physical exams, laboratory tests, and imaging to monitor tumor response and safety. Researchers measure outcomes like objective response rate, disease control rate, and duration of response. Monitoring continues through a follow-up period after treatment ends to evaluate lasting effects and drug safety. The study plans to enroll up to 250 participants aged 18 to 75 years.
Actively Recruiting
Researchers are evaluating the safety, tolerability, pharmacokinetics, and preliminary effectiveness of TQB3019 capsules in adults with advanced malignant tumors. This Phase 1 clinical trial uses a single-center, open, non-randomized, single-arm design to study patients with recurrent or refractory hematological cancers. Participants must meet specific health criteria, including physical status and organ function, to join the study. Participants receive TQB3019 capsules orally once daily, with doses ranging from 25 to 600 mg depending on the group. The trial includes two phases dose escalation and dose expansion. Treatment cycles last 28 days, and dosing may be single or continuous. The study monitors various outcomes such as dose limiting toxicity, maximum tolerated dose, and recommended phase II dose, along with adverse events and response rates. During the trial, participants undergo regular assessments including pharmacokinetic sampling at multiple time points, evaluation of protein levels, and monitoring of adverse effects up to about three years. Researchers measure overall response rates, disease control, progression-free survival, and overall survival. Safety is closely tracked from the first dose until 28 days after the last dose or other anti-tumor treatments begin. The total study duration extends to approximately three years with ongoing follow-up.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating a new screening method combining blood multi-gene methylation and fecal biomarkers to detect cancers throughout the digestive tract early. This observational study focuses on individuals aged 45 to 74 who are scheduled for digestive tract endoscopy. The goal is to establish a novel system that improves early diagnosis by measuring the sensitivity and specificity of these combined biomarkers. Participants will provide blood and stool samples before undergoing the endoscopic examination. The samples will be tested for specific gene methylation and fecal markers such as the immunochemical test and calprotectin. After the initial screening and endoscopic procedures with pathological confirmation, participants will be followed for five years to monitor outcomes and validate the screening method. Throughout the study, researchers will collect data on the accuracy of the combined biomarkers compared to endoscopy results, as well as track the detection rates of precancerous lesions and various digestive tract cancers over time. The study will also monitor any complications related to endoscopic screening, such as bleeding or infection. Participants will be involved in baseline sample collection, endoscopy, and long-term follow-up visits over five years.
Actively Recruiting
Researchers are evaluating budoprutug, a humanized monoclonal antibody targeting CD19, in adults aged 18 to 65 years with active, seropositive systemic lupus erythematosus SLE who have not adequately responded to standard treatments. This Phase 1b2a, open-label study aims to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and early signs of efficacy of budoprutug in this patient group. Budoprutug is given as two intravenous infusions, administered 14 days apart, in escalating dose groups. The study includes multiple cohorts receiving different dose levels followed by a dose expansion cohort, all receiving single IV doses on Day 1 and Day 15. The study monitors how budoprutug affects B cells and immunoglobulin levels over time, among other treatment effects. Participants will be closely assessed up to 28 weeks after treatment, with evaluations including adverse events, laboratory tests, vital signs, electrocardiograms, and changes in disease activity scores such as SLEDAI-2K and urine protein creatinine ratio. Researchers will also monitor drug levels, immune responses, and changes in B-cell counts. The total participation duration extends through these assessments to gather comprehensive safety and pharmacodynamic data.
Actively Recruiting
Researchers are evaluating the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary efficacy of LBL-024 in patients with advanced malignant tumors in a phase III clinical study. This study includes patients who have failed previous standard treatments, lack standard treatment options, or are not suitable for such treatments. The trial consists of two parts a phase IIIa dose escalation and pharmacokinetic expansion phase, and a phase IIb pivotal single-arm clinical study. Participants receive LBL-024 injections at the maximum tolerated dose every three weeks. The phase IIIa part focuses on dose escalation, safety, and preliminary efficacy, while the phase IIb part serves as a single-arm registry study to further assess the treatment. The study evaluates the drugs pharmacokinetic characteristics and immune response throughout treatment. During the study, participants are closely monitored for dose-limiting toxicities within three weeks of the first dose and maximum tolerated dose completion. Researchers assess objective response rate, adverse events, immunogenicity, disease control rate, and progression-free survival. Follow-up visits occur up to 30 days after treatment discontinuation or withdrawal. The total study duration extends until December 2026.
Actively Recruiting
Researchers are evaluating HLX22 combined with trastuzumab and chemotherapy as a first-line treatment for patients with HER2-positive locally advanced or metastatic adenocarcinoma of the gastric or gastroesophageal junction. This phase 3, randomized, double-blind study compares this combination against trastuzumab plus chemotherapy with or without pembrolizumab. The trial aims to assess the efficacy and safety of adding HLX22 in this patient population. Participants will be randomly assigned in a 11 ratio to either the experimental group receiving HLX22 15 mgkg plus trastuzumab and chemotherapy XELOX with or without a placebo for pembrolizumab every three weeks, or the control group receiving placebo for HLX22 plus trastuzumab and chemotherapy XELOX with or without pembrolizumab also every three weeks. Treatment continues until clinical benefit is lost, intolerable side effects occur, death, withdrawal, or other protocol-specified reasons. Throughout the study, participants will have their disease progression monitored by an independent radiology review committee using RECIST v1.1 criteria for up to five years, along with overall survival and response rates. Safety will be regularly assessed by tracking adverse events. The study includes multiple assessments to evaluate treatment effects, and participants will be followed for long-term outcomes during the trial period.
Actively Recruiting
Researchers are evaluating AK112, a PD-1VEGF bispecific antibody, as a consolidation treatment for patients with limited stage small cell lung cancer who have not shown disease progression after concurrent chemoradiation therapy. This phase III, randomized, double-blind study aims to compare the effectiveness and safety of AK112 against a placebo in this specific patient group. Participants will receive either AK112 or a placebo intravenously every three weeks as consolidation therapy following their initial chemoradiation. The study includes two groups one receiving AK112 at a dose of 20 mgkg every three weeks, and the other receiving a matching placebo on the same schedule. Treatment continues under close monitoring to assess outcomes. Throughout the study, participants will undergo regular assessments including scans and evaluations to monitor progression-free survival and overall survival over approximately six years. Additional outcome measures include response rates and disease control rates assessed by both independent review and investigators, along with safety monitoring for adverse events. This long-term follow-up helps researchers understand how the treatments perform and their impact on patient health.
Actively Recruiting
Researchers are evaluating brenipatide, a drug given as a subcutaneous injection, compared to a placebo to understand its effects and safety in adults with moderate-to-severe Alcohol Use Disorder AUD. The study is a Phase 3, multicenter, randomized, double-blind trial sponsored by Eli Lilly and Company. The trial aims to assess changes in drinking patterns over a period of up to 56 weeks. Participants receive escalating doses of the study drug or placebo administered by subcutaneous injection. The study includes two experimental periods with LY3537031 and a placebo group. Participants will self-inject the study intervention, keep diaries, and complete questionnaires throughout the trial. The trial design includes random assignment to one of the study groups, and treatment is monitored over the full 56 weeks. During the study, participants will attend regular visits to monitor their alcohol consumption using the Timeline Followback method, assess alcohol cravings with the Penn Alcohol Craving Scale, and evaluate health outcomes including body weight and quality of life measures. Researchers will also study the drugs pharmacokinetics and the presence of anti-drug antibodies. Participation lasts about 56 weeks, with ongoing safety and efficacy assessments throughout this period.
Actively Recruiting
Researchers are evaluating new combination treatments for people with locally advanced or metastatic non-small cell lung cancer NSCLC in this Phase II, multi-center, open-label study. The study includes several sub-studies focused on different groups based on tumor genetics and PD-L1 levels, aiming to assess the safety, tolerability, and early anti-tumor effects of these novel regimens. This global study is conducted at approximately 80 centers across 10 countries. Participants receive different combinations of investigational drugs given by intravenous infusion, including rilvegostomig, ramucirumab, and Dato-DXd, depending on their assigned sub-study. Treatments continue until the cancer progresses, unacceptable side effects occur, or consent is withdrawn. Each sub-study may have a safety run-in phase followed by a dose expansion phase to further evaluate the treatments. Throughout the study, participants undergo regular assessments to monitor tumor response, side effects, and drug levels in the blood. Researchers will track adverse events and measure outcomes like objective response rate, progression-free survival, and overall survival over an average of three years. The study also evaluates pharmacokinetics and immune response to the treatments to better understand how they work and their safety profile.
1-10 of 54
1